|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.39 EUR | +1.13% |
|
+7.48% | -5.89% |
| 10:24am | FMC FRESENIUS MEDICAL CARE AG : UBS keeps a Sell rating | ZD |
| 06-08 | Clínica Baviera, the copy-paste machine |
| Fiscal Period: December | 2016 | 2017 (EUR) | 2018 (EUR) | 2019 (EUR) | 2020 (EUR) | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.49 | 2.81 | 2.73 | 2.85 | 3.62 | |||||
Return on Total Capital | 4.43 | 3.52 | 3.43 | 3.58 | 4.51 | |||||
Return On Equity % | 9.27 | 6.08 | 4.84 | 4.84 | 7.93 | |||||
Return on Common Equity | 8.11 | 5.05 | 3.61 | 3.82 | 7.02 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 28.82 | 27.38 | 25.32 | 24.6 | 25.62 | |||||
SG&A Margin | 17.1 | 18.07 | 16.43 | 16.25 | 15.45 | |||||
EBITDA Margin % | 15.26 | 12.83 | 12.23 | 12.14 | 13.36 | |||||
EBITA Margin % | 11.05 | 8.68 | 8.32 | 8.4 | 9.92 | |||||
EBIT Margin % | 10.47 | 8.12 | 7.83 | 7.96 | 9.53 | |||||
Income From Continuing Operations Margin % | 6.92 | 4.61 | 3.77 | 3.83 | 6.07 | |||||
Net Income Margin % | 5.5 | 3.47 | 2.56 | 2.78 | 4.98 | |||||
Net Avail. For Common Margin % | 5.5 | 3.47 | 2.56 | 2.78 | 4.98 | |||||
Normalized Net Income Margin | 4.46 | 3.21 | 2.89 | 3.2 | 4.31 | |||||
Levered Free Cash Flow Margin | 9.42 | 5.4 | 6.74 | 10.5 | 7.93 | |||||
Unlevered Free Cash Flow Margin | 10.67 | 6.56 | 8.11 | 11.82 | 9.15 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.53 | 0.55 | 0.56 | 0.57 | 0.61 | |||||
Fixed Assets Turnover | 2.11 | 2.3 | 2.46 | 2.63 | 2.85 | |||||
Receivables Turnover (Average Receivables) | 5.15 | 5.31 | 5.29 | 5.49 | 5.96 | |||||
Inventory Turnover (Average Inventory) | 6.38 | 6.5 | 6.49 | 6.87 | 6.94 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.1 | 1.27 | 1.42 | 1.4 | 1.26 | |||||
Quick Ratio | 0.76 | 0.85 | 0.91 | 0.91 | 0.85 | |||||
Operating Cash Flow to Current Liabilities | 0.34 | 0.34 | 0.43 | 0.42 | 0.43 | |||||
Days Sales Outstanding (Average Receivables) | 70.89 | 68.68 | 69.03 | 66.69 | 61.23 | |||||
Days Outstanding Inventory (Average Inventory) | 57.24 | 56.15 | 56.22 | 53.31 | 52.61 | |||||
Average Days Payable Outstanding | 23.21 | 21.77 | 21.93 | 22.7 | 22.09 | |||||
Cash Conversion Cycle (Average Days) | 104.91 | 103.06 | 103.31 | 97.3 | 91.75 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 95.29 | 85.52 | 81.46 | 69.79 | 75.68 | |||||
Total Debt / Total Capital | 48.79 | 46.1 | 44.89 | 41.1 | 43.08 | |||||
LT Debt/Equity | 76.79 | 72.34 | 70.74 | 61.9 | 60.2 | |||||
Long-Term Debt / Total Capital | 39.32 | 38.99 | 38.99 | 36.46 | 34.27 | |||||
Total Liabilities / Total Assets | 59.32 | 56.79 | 56.3 | 53.02 | 53.93 | |||||
EBIT / Interest Expense | 5.22 | 4.38 | 3.59 | 3.78 | 4.86 | |||||
EBITDA / Interest Expense | 9.56 | 8.98 | 7.25 | 7.42 | 8.51 | |||||
(EBITDA - Capex) / Interest Expense | 7.14 | 6.97 | 5.64 | 5.71 | 6.13 | |||||
Total Debt / EBITDA | 3.94 | 4.09 | 3.92 | 3.64 | 3.31 | |||||
Net Debt / EBITDA | 3.46 | 3.63 | 3.42 | 3.2 | 2.77 | |||||
Total Debt / (EBITDA - Capex) | 5.27 | 5.26 | 5.04 | 4.74 | 4.59 | |||||
Net Debt / (EBITDA - Capex) | 4.62 | 4.68 | 4.39 | 4.16 | 3.85 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -1.35 | 10.1 | 0.29 | -0.61 | 1.51 | |||||
Gross Profit, 1 Yr. Growth % | -8.34 | 4.56 | 0.64 | -3.42 | 5.72 | |||||
EBITDA, 1 Yr. Growth % | -16.46 | -7.55 | -2.88 | -1.36 | 11.75 | |||||
EBITA, 1 Yr. Growth % | -21.53 | -13.61 | -1.56 | 0.28 | 19.95 | |||||
EBIT, 1 Yr. Growth % | -22.5 | -14.61 | -0.94 | 1.04 | 21.47 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -15.1 | -26.64 | -18.1 | 1.15 | 60.79 | |||||
Net Income, 1 Yr. Growth % | -16.75 | -30.53 | -25.9 | 7.8 | 81.88 | |||||
Normalized Net Income, 1 Yr. Growth % | -24.85 | -20.77 | -2.37 | 10.12 | 36.43 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -16.44 | -30.6 | -25.97 | 7.65 | 83.6 | |||||
Accounts Receivable, 1 Yr. Growth % | 9.71 | 3.89 | -2.2 | -6.29 | -6.84 | |||||
Inventory, 1 Yr. Growth % | 7.53 | 12.67 | -5.1 | -5.11 | 3.52 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 4.45 | -2.48 | -10.62 | -2.62 | -10.45 | |||||
Total Assets, 1 Yr. Growth % | 8.45 | 4.04 | -5.1 | -1.07 | -7.64 | |||||
Tangible Book Value, 1 Yr. Growth % | -0.08 | 6.35 | -27.96 | -17.89 | -22.81 | |||||
Common Equity, 1 Yr. Growth % | 13.23 | 10.16 | -2.64 | 7.02 | -8.69 | |||||
Cash From Operations, 1 Yr. Growth % | -41.19 | -12.94 | 21.29 | -9.23 | 12.36 | |||||
Capital Expenditures, 1 Yr. Growth % | -18.79 | -15.26 | -5.44 | 2.16 | 30.89 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -29.6 | -36.97 | 28.29 | 54.8 | -23.37 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -28.05 | -32.41 | 26.42 | 44.88 | -21.39 | |||||
Dividend Per Share, 1 Yr. Growth % | 0.75 | -17.04 | 6.25 | 21.01 | 3.47 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 0.41 | 4.22 | 5.08 | -0.16 | 0.45 | |||||
Gross Profit, 2 Yr. CAGR % | -3 | -2.07 | 1.58 | -1.41 | 1.05 | |||||
EBITDA, 2 Yr. CAGR % | -7.41 | -12.65 | -7.8 | -3.34 | 3.76 | |||||
EBITA, 2 Yr. CAGR % | -10.29 | -18.31 | -11.25 | -2.46 | 7.81 | |||||
EBIT, 2 Yr. CAGR % | -10.14 | -18.58 | -10.54 | 0.05 | 10.78 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -7.94 | -21.08 | -22.49 | -8.98 | 27.53 | |||||
Net Income, 2 Yr. CAGR % | -10.11 | -23.95 | -28.25 | -10.62 | 40.02 | |||||
Normalized Net Income, 2 Yr. CAGR % | -9.84 | -22.74 | -17 | 3.69 | 22.57 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -8.59 | -23.85 | -28.32 | -10.73 | 40.58 | |||||
Accounts Receivable, 2 Yr. CAGR % | -0.16 | 6.76 | 0.8 | -4.27 | -6.57 | |||||
Inventory, 2 Yr. CAGR % | 10.69 | 10.07 | 3.41 | -5.1 | -0.89 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 0.21 | 0.93 | -6.64 | -6.71 | -6.62 | |||||
Total Assets, 2 Yr. CAGR % | 2.15 | 6.22 | -0.64 | -3.11 | -4.41 | |||||
Tangible Book Value, 2 Yr. CAGR % | -5.36 | 3.08 | -12.47 | -23.09 | -20.39 | |||||
Common Equity, 2 Yr. CAGR % | 3.05 | 11.69 | 3.56 | 2.08 | -1.15 | |||||
Cash From Operations, 2 Yr. CAGR % | -1.52 | -28.45 | 2.76 | 4.93 | 0.99 | |||||
Capital Expenditures, 2 Yr. CAGR % | -12.85 | -17.04 | -10.48 | -1.72 | 15.63 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 19.32 | -33.35 | -12.06 | 40.92 | 8.91 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 13.01 | -30.23 | -9.3 | 35.34 | 6.72 | |||||
Dividend Per Share, 2 Yr. CAGR % | 6.07 | -8.58 | -6.11 | 13.39 | 11.9 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 2.11 | 3.54 | 2.89 | 3.15 | 0.39 | |||||
Gross Profit, 3 Yr. CAGR % | -0.51 | -0.53 | -3.83 | -0.11 | 0.91 | |||||
EBITDA, 3 Yr. CAGR % | -2.58 | -7.43 | -9.97 | -5.7 | 1.45 | |||||
EBITA, 3 Yr. CAGR % | -5.09 | -11.39 | -13.73 | -7.57 | 4.5 | |||||
EBIT, 3 Yr. CAGR % | -5.48 | -11.63 | -13.79 | -6.84 | 6.73 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -18.18 | -14.65 | -20.1 | -15.3 | 10.03 | |||||
Net Income, 3 Yr. CAGR % | -21.21 | -17.51 | -24.61 | -17.82 | 13.26 | |||||
Normalized Net Income, 3 Yr. CAGR % | -7.09 | -13.6 | -18.62 | -8.79 | 13.62 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -19.95 | -16.61 | -24.56 | -17.92 | 13.53 | |||||
Accounts Receivable, 3 Yr. CAGR % | 1.44 | 1.17 | 3.69 | -1.62 | -5.13 | |||||
Inventory, 3 Yr. CAGR % | 11.59 | 11.35 | 4.76 | 0.49 | -2.31 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 30.63 | -0.69 | -3.08 | -5.32 | -7.97 | |||||
Total Assets, 3 Yr. CAGR % | 9.41 | 2.78 | 2.3 | -0.78 | -4.64 | |||||
Tangible Book Value, 3 Yr. CAGR % | 40.22 | -1.61 | -8.52 | -14.31 | -23 | |||||
Common Equity, 3 Yr. CAGR % | 2.6 | 5.37 | 6.69 | 4.7 | -1.65 | |||||
Cash From Operations, 3 Yr. CAGR % | 6.48 | -5.48 | -14.68 | -1.4 | 7.35 | |||||
Capital Expenditures, 3 Yr. CAGR % | -6.86 | -13.66 | -13.34 | -6.46 | 8.13 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 31.91 | -3.52 | -17.72 | 6.18 | 15.02 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 23.3 | -4.77 | -15.47 | 6.02 | 12.92 | |||||
Dividend Per Share, 3 Yr. CAGR % | 4.89 | -2.27 | -3.88 | 2.17 | 9.98 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 1.24 | 1.75 | 3.29 | 2.04 | 1.91 | |||||
Gross Profit, 5 Yr. CAGR % | -2 | -2.47 | -0.91 | -2.49 | -1.91 | |||||
EBITDA, 5 Yr. CAGR % | -2.41 | -3.69 | -3.94 | -5.64 | -4.26 | |||||
EBITA, 5 Yr. CAGR % | -4.45 | -6.69 | -6.59 | -7.66 | -5.04 | |||||
EBIT, 5 Yr. CAGR % | -4.62 | -7.01 | -6.95 | -7.58 | -4.69 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -3.01 | -10.47 | -19.93 | -12.43 | -3.67 | |||||
Net Income, 5 Yr. CAGR % | -3.26 | -12.05 | -24.11 | -14.82 | -3.42 | |||||
Normalized Net Income, 5 Yr. CAGR % | -4.6 | -8.21 | -10.49 | -8.51 | -4.14 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -2.37 | -11.2 | -23.41 | -14.31 | -3.23 | |||||
Accounts Receivable, 5 Yr. CAGR % | -0.66 | 1.22 | 1.18 | -1.04 | -0.54 | |||||
Inventory, 5 Yr. CAGR % | 8.79 | 12.21 | 8.24 | 4.45 | 2.47 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 19.03 | 19.02 | 14.21 | -3.14 | -4.51 | |||||
Total Assets, 5 Yr. CAGR % | 6.15 | 8.28 | 5.27 | 0.38 | -0.44 | |||||
Tangible Book Value, 5 Yr. CAGR % | -3.76 | 2.28 | 16.13 | -10.84 | -13.47 | |||||
Common Equity, 5 Yr. CAGR % | 4.94 | 7.33 | 2.98 | 4.04 | 3.48 | |||||
Cash From Operations, 5 Yr. CAGR % | 5.2 | -0.22 | 4.98 | -1.45 | -8.73 | |||||
Capital Expenditures, 5 Yr. CAGR % | -1.69 | -5.18 | -8.33 | -9.07 | -2.74 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 2.26 | -1.55 | 12.66 | 11.75 | -7.96 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 1.44 | -1.79 | 9.48 | 9.19 | -7.21 | |||||
Dividend Per Share, 5 Yr. CAGR % | 7.06 | 1.11 | 0.34 | 3.71 | 2.14 |
- Stock Market
- Stocks
- FME Stock
- Financials Fresenius Medical Care AG
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















